“Cutting Edge” article demonstrates that compared with IL-2, TNFR2 agonism promotes tissue-directed regulatory T-cell differentiation and lineage stability, as well as reduces autoimmune inflammation in preclinical models Company’s investigational TNFR2 agonist, OD-003, expected to complete IND-enabling studies in the first quarter of 2027 BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to tr ...